IP Library › Granted Patent US 8,329,439
Granted Patent B2
US 8,329,439 · App. 12/665,656 · Granted Dec 11, 2012

Glucose dehydrogenase

Assignees: ARKRAY, Inc.; Ultizyme International Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,329,439
App. No.
12/665,656
Granted
Dec 11, 2012
Kind
B2
Abstract

A modified pyrroloquinoline quinone glucose dehydrogenase that exhibits a high selectivity for glucose is provided. A modified pyrroloquinoline quinone glucose dehydrogenase is disclosed in which the amino acid residue G at Position 99 of a pyrroloquinoline quinone glucose dehydrogenase (PQQGDH) represented by SEQ ID NO: 1, or the amino acid residue G at Position 100 of the pyrroloquinoline quinone glucose dehydrogenase (PQQGDH) represented by SEQ ID NO: 3, is substituted by the amino acid sequence TGZN (where Z is SX, S, or N and X is any amino acid residue). The modified PQQGDH of the present invention may additionally comprise one or more mutations selected from the group consisting of Q192G, Q192A, or Q192S; L193X; E277X; A318X; Y367A, Y367F, or Y367W; G451C; and N452X (where X is any amino acid residue).

Claims (56)

1. A modified pyrroloquinoline quinone glucose dehydrogenase, wherein the amino acid residue G at Position 99 of a pyrroloquinoline quinone glucose dehydrogenase (PQQGDH) represented by SEQ ID NO: 1 is substituted by the amino acid sequence TGZN (where Z is SX, S, or N and X is any amino acid residue), and wherein from 1 to 10 of amino acid residues at Positions 1 to 98 or at Positions 100 to 478 of SEQ ID NO: 1, may be substituted by any other amino acid residue(s).

2. The modified pyrroloquinoline quinone glucose dehydrogenase according to claim 1 , wherein Z is SX (where X is any amino acid residue).

3. The modified pyrroloquinoline quinone glucose dehydrogenase according to claim 1 , wherein Z is SN.

4. The modified pyrroloquinoline quinone glucose dehydrogenase according to claim 1 , further comprising one or more mutations selected from the group consisting of the following amino acid substitutions:

Q192G, Q192A, or Q192S;

L193X (where X is any amino acid residue);

E277X (where X is any amino acid residue);

A318X (where X is any amino acid residue);

Y367A, Y367F, or Y367W;

G451C; and

N452X (where X is any amino acid residue).

5. The modified pyrroloquinoline quinone glucose dehydrogenase according to claim 4 , comprising any of the following combinations of amino acid mutations:

G99(TGSXN)+Q192G+L193E;

G99(TGSXN)+Q192S+N452P;

G99(TGSXN)+Q192G+L193E+N452P;

G99(TGSXN)+Q192S+N452P;

G99(TGSNN)+N452P;

G99(TGSNN)+Q192G+L193E+N452P;

G99(TGSNN)+Q192S+N452P;

G99(TGSNN)+Q192G+N452P;

G99(TGSNN)+L193E+N452P;

G99(TGSNN)+Q192S+L193M+N452P;

G99(TGSNN)+A318Y+N452P;

G99(TGSNN)+Q192G;

G99(TGSNN)+Q192S;

G99(TGSNN)+Q192A;

G99(TGSNN)+Q192G+L193E;

G99(TGSNN)+Q192S+L193X;

G99(TGSNN)+Q192S+L193M;

G99(TGSNN)+Q192S+L193T;

G99(TGSNN)+Q192S+E277X;

G99(TGSNN)+Q192S+N452X;

G99(TGSNN)+Q192S+L193X+A318Y+N452P;

G99(TGSNN)+Q192S+A318X+N452P;

G99(TGSNN)+Q192G+L193E+A318X+N452P;

G99(TGSKN)+Q192S+N452P;

G99(TGSRN)+Q192S+N452P;

G99(TGSWN)+Q192S+N452P;

G99(TGSN)+Q192S+N452P;

G99(TGSN)+Q192G+L193E;

G99(TGSN)+Q192S+L193M;

G99(TGNN)+Q192S+N452P;

G99(TGNN)+Q192G+L193E; or

G99(TGNN)+Q192S+L193M

where X is any amino acid residue.

6. The modified pyrroloquinoline quinone glucose dehydrogenase according to claim 5 , comprising any of the following combinations of amino acid mutations:

G99(TGSXN)+Q192G+L193E;

G99(TGSXN)+Q192S+N452P;

G99(TGSNN)+Q192G+L193E+N452P;

G99(TGSNN)+Q192S+L193M+N452P;

G99(TGSNN)+Q192G+L193E+A318K+N452P; or

G99(TGSNN)+Q192G+L193E+A318Q+N452P.

7. A method for analyzing glucose level using the modified pyrroloquinoline quinone glucose dehydrogenase according to claim 1 .

8. A glucose assay kit comprising the modified pyrroloquinoline quinone glucose dehydrogenase according to claim 1 .

9. An enzyme electrode comprising the modified pyrroloquinoline quinone glucose dehydrogenase according to claim 1 .

10. A glucose sensor comprising the enzyme electrode according to claim 9 as a working electrode.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY DATA FROM ARKRAY, INC. TO ARKRAY, INC. AND ULTIZYME INTERNATIONAL LTD. PREVIOUSLY RECORDED ON REEL 027894 FRAME 0384. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF ASSIGNORS INTEREST. Recorded Apr 16, 2012
From: ULTIZYME INTERNATIONAL LTD.
To: ARKRAY, INC.; ULTIZYME INTERNATIONAL LTD.
Reel/Frame 028054/0738 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 20, 2012
From: ULTIZYME INTERNATIONAL LTD.
To: ARKRAY, INC.
Reel/Frame 027894/0384 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 27, 2010
From: SODE, KOJI
To: ULTIZYME INTERNATIONAL LTD.
Reel/Frame 025048/0140 →
Priority Claims (1)
JP 2007-163858 · Jun 21, 2007 · national
Continuity (1)
Related Publication 20120142037A1 · Jun 7, 2012